Achyut Healthcare Limited has received in-principle approval from BSE Limited for a preferential issue of equity shares, marking a significant step in the company's capital raising initiative. The approval was communicated through BSE's letter dated March 11, 2026, and subsequently disclosed by the company on March 12, 2026.

Preferential Issue Details

The BSE has granted approval for the issuance of substantial equity shares under specific terms and conditions:

Regulatory Compliance Requirements

BSE has outlined comprehensive compliance requirements that the company must fulfill before proceeding with the allotment. The approval is subject to strict adherence to multiple regulatory frameworks including:

• Companies Act, 2013
• Securities Contracts (Regulation) Act, 1956
• Securities and Exchange Board of India Act, 1992
• Depositories Act, 1996
• SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018
• SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Key Compliance Measures

The exchange has mandated specific internal control measures to ensure regulatory compliance:

• Trading Restrictions: The company must obtain undertakings from allottees confirming they will not engage in intra-day trading or sell shares until the allotment date
• Verification Responsibility: Complete onus lies on the issuer company to verify compliance with SEBI ICDR Regulations, particularly Regulation 167(6)
• Listing Timeline: Application for listing must be made within twenty days from the date of allotment as per SEBI circular dated June 21, 2023

Post-Allotment Obligations

Upon completion of the allotment, Achyut Healthcare Limited will be required to submit a listing application with applicable fees under Regulation 14 of LODR Regulations. The company must also complete all post-issue formalities as specified by the exchange.

Important Disclaimers

BSE has clarified that this in-principle approval should not be construed as approval for listing of the securities. The exchange reserves the right to withdraw approval if any information is found to be incomplete, incorrect, misleading, or in contravention of applicable regulations. Any non-compliance with the twenty-day listing application requirement will attract penalties as specified in the relevant SEBI circular.

Achyut Healthcare Limited announced its unaudited financial results for the quarter ended December 31, 2025, along with several strategic corporate developments approved by its Board of Directors on January 21, 2026. The pharmaceutical trading company reported mixed quarterly performance while outlining ambitious expansion plans through capital restructuring and fundraising initiatives.

Financial Performance for Q3FY26

The company's financial results for the quarter ended December 31, 2025, showed total income of ₹161.12 lakhs, comprising revenue from operations of ₹156.96 lakhs and other income of ₹4.16 lakhs. Net profit for the quarter stood at ₹0.43 lakhs after accounting for total expenses of ₹160.23 lakhs and tax expenses of ₹0.46 lakhs.

For the nine months ended December 31, 2025, the company achieved total income of ₹744.59 lakhs with net profit of ₹23.73 lakhs, compared to ₹286.91 lakhs income and ₹38.59 lakhs profit in the corresponding period of the previous year.

Preferential Issue and Capital Expansion

The Board approved a significant preferential issue of up to 58 lakh equity shares of ₹1 face value each at an issue price of ₹6 per share, including a premium of ₹5 per share. The total issue size amounts to ₹3.48 crores and will be allocated to both promoter and non-promoter categories.

The preferential allotment includes allocations to promoter entities such as Akshit Mahendra Raycha (8 lakh shares), Mahendra C. Raycha HUF (8 lakh shares), and non-promoter investors including Strikar Lifescience LLP (18 lakh shares) and individual investors Dhavalkumar and Mayankbhai Ruparelia (10 lakh shares each).

Authorized Capital Enhancement

To facilitate future fundraising activities, the Board approved increasing the company's authorized capital from ₹24 crores to ₹26 crores. This enhancement will require corresponding amendments to Clause V of the Memorandum of Association, subject to shareholder approval. The revised authorized capital will comprise 26 crore equity shares of ₹1 each.

Corporate Developments

The company announced the relocation of its registered office within Ahmedabad city limits from 610 Colonade, Iscon-Ambali Road to 504, Iscon Elegance, Circle P, S.G. Highway, Ahmedabad-380015. The Board stated this move will facilitate expansion of operations, provide larger workspace, and better accommodate growing administrative requirements.

Platform Migration and Compliance

Achyut Healthcare successfully migrated from BSE SME platform to BSE Main Board, with equity shares commencing trading on the main board from January 2, 2026. Consequently, the company adopted Indian Accounting Standards (Ind AS) effective April 1, 2025, with the transition date being April 1, 2024. The current quarterly results represent the third unaudited quarterly financial results prepared under Ind AS framework.

The Board has scheduled an Extraordinary General Meeting on February 19, 2026, to seek shareholder approval for the preferential issue, authorized capital increase, and related amendments to the Memorandum of Association.